Combined EGFR/MEK inhibition prevents the emergence of resistance in EGFR-mutant lung cancer
Drug Resistance, Neoplasm
Mitogen-Activated Protein Kinase Kinases
Protein Kinase Inhibitors
Receptor, Epidermal Growth Factor
Patients with EGFR-mutant lung cancer develop acquired resistance to EGFR and mutant-selective EGFR tyrosine kinase inhibitors. Here, we show that cotargeting EGFR and MEK can prevent the emergence of a broad variety of drug resistance mechanisms in vitro and in vivo and may be a superior therapeutic regimen for these patients.